Our recent publications

Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins G3 for the ^99mTc-Based Imaging of HER2-Expressing Malignant Tumors

Larkina, Maria; Varvashenya, Ruslan; Yuldasheva, Feruza; Plotnikov, Evgenii et al.

Part of Molecular Pharmaceutics, p. 1919-1932, 2024

• DOI for Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins G3 for the ^99mTc-Based Imaging of HER2-Expressing Malignant Tumors

Comparison of approaches for increasing affinity of affibody molecules for imaging of B7-H3: dimerization and affinity maturation

Oroujeni, Maryam; Carlqvist, Matilda; Ryer, Eva; Orlova, Anna et al.

Part of EJNMMI Radiopharmacy and Chemistry, 2024

• DOI for Comparison of approaches for increasing affinity of affibody molecules for imaging of B7-H3: dimerization and affinity maturation
• Download full text (pdf) of Comparison of approaches for increasing affinity of affibody molecules for imaging of B7-H3: dimerization and affinity maturation

Den senaste utvecklingen av radionuklidbaserade teranostiska medel inriktad mot PSMA vid prostatacancer

Kahoori, Sahar

2024

GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics

Obeid, Karim; Kanellopoulos, Panagiotis; Abouzayed, Ayman; Mattsson, Adam et al.

Part of Pharmaceutics, 2024

• DOI for GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics
• Download full text (pdf) of GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics

Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.

Zhang, Jie; Bodenko, Vitalina; Larkina, Maria; Bezverkhniaia, Ekaterina et al.

Part of Journal of Controlled Release, p. 468-478, 2024

• DOI for Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.
• Download full text (pdf) of Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.

Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m

Bezverkhniaia, Ekaterina; Kanellopoulos, Panagiotis; Rosenström, Ulrika; Tolmachev, Vladimir et al.

Part of International Journal of Molecular Sciences, 2024

• DOI for Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m
• Download full text (pdf) of Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m

Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion

Deyev, Sergey M.; Oroujeni, Maryam; Garousi, Javad; Graeslund, Torbjoern et al.

Part of International Journal of Molecular Sciences, 2024

• DOI for Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion
• Download full text (pdf) of Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion

Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology

Kanellopoulos, Panagiotis; Mattsson, Adam; Abouzayed, Ayman; Obeid, Karim et al.

Part of EJNMMI Radiopharmacy and Chemistry, 2024

• DOI for Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology
• Download full text (pdf) of Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology

Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled with ¹⁷⁷Lu

Machulkin, Aleksei E.; Petrov, Stanislav A.; Bodenko, Vitalina; Larkina, Mariia S. et al.

Part of ACS Pharmacology & Translational Science, p. 1457-1473, 2024

• DOI for Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled with ¹⁷⁷Lu

Two Novel [⁶⁸Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar¹¹]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer

Kanellopoulos, Panagiotis; Bezverkhniaia, Ekaterina; Abouzayed, Ayman; Rosenström, Ulrika et al.

Part of ACS Omega, p. 18608-18616, 2024

• DOI for Two Novel [⁶⁸Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar¹¹]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer
• Download full text (pdf) of Two Novel [⁶⁸Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar¹¹]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer

¹⁷⁷Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry

Abouzayed, Ayman; Seitova, Kamila; Lundmark, Fanny; Bodenko, Vitalina et al.

Part of Frontiers in Oncology, 2023

• DOI for ¹⁷⁷Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry
• Download full text (pdf) of ¹⁷⁷Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry

Co-injection of anti-HER2 antibody Trastuzumab does not increase efficacy of [Lu-177]Lu-PSMA-617 therapy in an animal model of prostate cancer

Abouzayed, Ayman; Zedan, Wahed; Altai, Mohamed; Strand, Joanna et al.

Part of American Journal of Nuclear Medicine and Molecular Imaging, p. 107-+, 2023

Comparison of HER2-targeted affibody conjugates loaded with auristatin-and maytansine-derived drugs

Yin, Wen; Xu, Tianqi; Ding, Haozhong; Zhang, Jie et al.

Part of Journal of Controlled Release, p. 515-527, 2023

• DOI for Comparison of HER2-targeted affibody conjugates loaded with auristatin-and maytansine-derived drugs

Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity

Leitao, Charles Dahlsson; Borras, Anna Mestre; Xu, Tianqi; Oroujeni, Maryam et al.

Part of Journal of Controlled Release, p. 185-195, 2023

• DOI for Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity

Development of a PNA-drug conjugate for pretargeted delivery of cytotoxic drugs

Haraldsson, Astrid

2023

• Download full text (pdf) of Development of a PNA-drug conjugate for pretargeted delivery of cytotoxic drugs

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model

Xu, Tianqi; Schulga, Alexey; Konovalova, Elena; Rinne, Sara S. et al.

Part of International Journal of Molecular Sciences, 2023

• DOI for Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model
• Download full text (pdf) of Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model

Phase I Trial of [Tc-99m]Tc-maSSS-PEG(2)-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors

Chernov, Vladimir; Rybina, Anastasiya; Zelchan, Roman; Medvedeva, Anna et al.

Part of Cancers, 2023

• DOI for Phase I Trial of [Tc-99m]Tc-maSSS-PEG(2)-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors
• Download full text (pdf) of Phase I Trial of [Tc-99m]Tc-maSSS-PEG(2)-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors

Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [Ga-68]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation

Lundmark, Fanny; Abouzayed, Ayman; Rinne, Sara S.; Timofeev, Vasiliy et al.

Part of Cancers, 2023

• DOI for Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [Ga-68]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation
• Download full text (pdf) of Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [Ga-68]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation

Preclinical Evaluation of a Novel High-Affinity Radioligand [^99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA)

Bezverkhniaia, Ekaterina; Kanellopoulos, Panagiotis; Abouzayed, Ayman; Larkina, Mariia et al.

Part of International Journal of Molecular Sciences, 2023

• DOI for Preclinical Evaluation of a Novel High-Affinity Radioligand [^99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA)
• Download full text (pdf) of Preclinical Evaluation of a Novel High-Affinity Radioligand [^99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA)

Preclinical evaluation of novel therapeutical GRPR-targeting antagonists labeled with ¹¹¹In

Mattsson, Adam

2023

Radionuclide Therapy of HER2-Expressing Xenografts Using [Lu-177]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab

Liu, Yongsheng; Xu, Tianqi; Vorobyeva, Anzhelika; Loftenius, Annika et al.

Part of Cancers, 2023

• DOI for Radionuclide Therapy of HER2-Expressing Xenografts Using [Lu-177]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
• Download full text (pdf) of Radionuclide Therapy of HER2-Expressing Xenografts Using [Lu-177]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab

Synthesis, I-123-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures

Hasnowo, Lutfi A.; Larkina, Maria S.; Plotnikov, Evgenii; Bodenko, Vitalina et al.

Part of International Journal of Molecular Sciences, 2023

• DOI for Synthesis, I-123-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures
• Download full text (pdf) of Synthesis, I-123-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures

The GRPR Antagonist [^99mTc]Tc-maSSS-PEG₂-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity

Abouzayed, Ayman; Borin, Jesper; Lundmark, Fanny; Rybina, Anastasiya et al.

Part of Diagnostics, 2023

• DOI for The GRPR Antagonist [^99mTc]Tc-maSSS-PEG₂-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity
• Download full text (pdf) of The GRPR Antagonist [^99mTc]Tc-maSSS-PEG₂-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity

Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with Tc-99m and I-125

Tolmachev, Vladimir; Bodenko, Vitalina; Orlova, Anna; Schulga, Alexey et al.

Part of Oncology Letters, 2023

• DOI for Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with Tc-99m and I-125
• Download full text (pdf) of Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with Tc-99m and I-125

Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis

Liu, Yongsheng; Gueler, Rezan; Liao, Yunqi; Vorobyeva, Anzhelika et al.

Part of Pharmaceutics, 2022

• DOI for Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis
• Download full text (pdf) of Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis

Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands

Lundmark, Fanny; Olanders, Gustav; Rinne, Sara Sophie; Abouzayed, Ayman et al.

Part of Pharmaceutics, 2022

• DOI for Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands
• Download full text (pdf) of Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands

Direct In Vivo Comparison of ^99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy

Tolmachev, Vladimir; Bodenko, Vitalina; Oroujeni, Maryam; Deyev, Sergey et al.

Part of International Journal of Molecular Sciences, 2022

• DOI for Direct In Vivo Comparison of ^99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy
• Download full text (pdf) of Direct In Vivo Comparison of ^99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy

Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2

Xu, Tianqi; Zhang, Jie; Oroujeni, Maryam; Tretyakova, Maria S. et al.

Part of Pharmaceutics, 2022

• DOI for Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2
• Download full text (pdf) of Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2

Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule ¹⁸⁸Re-ZHER2:41071

Liu, Yongsheng; Vorobyeva, Anzhelika; Orlova, Anna; Konijnenberg, Mark W. et al.

Part of Pharmaceutics, 2022

• DOI for Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule ¹⁸⁸Re-ZHER2:41071
• Download full text (pdf) of Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule ¹⁸⁸Re-ZHER2:41071

In vitro characterization of affibody molecules intended for therapy of EGFR-expressing cancer

Mahmod, Chenar

2022

PET-CT imaging of pulmonary inflammation using [Ga-68]Ga-DOTA-TATE

Puuvuori, Emmi; Liggieri, Francesco; Velikyan, Irina; Chiodaroli, Elena et al.

Part of EJNMMI Research, 2022

• DOI for PET-CT imaging of pulmonary inflammation using [Ga-68]Ga-DOTA-TATE
• Download full text (pdf) of PET-CT imaging of pulmonary inflammation using [Ga-68]Ga-DOTA-TATE

Phase I Trial of ^99mTc-(HE)₃-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer

Bragina, Olga; Chernov, Vladimir; Schulga, Alexey; Konovalova, Elena et al.

Part of Journal of Nuclear Medicine, p. 528-535, 2022

• DOI for Phase I Trial of ^99mTc-(HE)₃-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer

Preclinical Evaluation of a New Format of Ga-68- and In-111-Labeled Affibody Molecule Z(IGF-1R:4551) for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT

Liu, Yongsheng; Yu, Shengze; Xu, Tianqi; Bodenko, Vitalina et al.

Part of Pharmaceutics, 2022

• DOI for Preclinical Evaluation of a New Format of Ga-68- and In-111-Labeled Affibody Molecule Z(IGF-1R:4551) for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT
• Download full text (pdf) of Preclinical Evaluation of a New Format of Ga-68- and In-111-Labeled Affibody Molecule Z(IGF-1R:4551) for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT

Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules

Rinne, Sara S.; Yin, Wen; Borras, Anna Mestre; Abouzayed, Ayman et al.

Part of Biomedicines, 2022

• DOI for Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules
• Download full text (pdf) of Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules

The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer

Li, Mei; Zelchan, Roman; Orlova, Anna

Part of Biomedicines, 2022

• DOI for The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer
• Download full text (pdf) of The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer

A method of drug delivery to tumors based on rapidly biodegradable drug-loaded containers

Parakhonskiy, Bogdan, V; Shilyagina, Natalia Yu; Gusliakova, Olga, I; Volovetskiy, Artur B. et al.

Part of APPLIED MATERIALS TODAY, 2021

• DOI for A method of drug delivery to tumors based on rapidly biodegradable drug-loaded containers

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution

Ding, Haozhong; Xu, Tianqi; Zhang, Jie; Tolmachev, Vladimir et al.

Part of Pharmaceutics, 2021

• DOI for Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
• Download full text (pdf) of Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody^® Molecules ¹⁷⁷Lu-ABY-271 and ¹⁷⁷Lu-ABY-027: Impact of DOTA Position on ABD Domain

Liu, Yongsheng; Vorobyeva, Anzhelika; Xu, Tianqi; Orlova, Anna et al.

Part of Pharmaceutics, 2021

• DOI for Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody^® Molecules ¹⁷⁷Lu-ABY-271 and ¹⁷⁷Lu-ABY-027: Impact of DOTA Position on ABD Domain
• Download full text (pdf) of Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody^® Molecules ¹⁷⁷Lu-ABY-271 and ¹⁷⁷Lu-ABY-027: Impact of DOTA Position on ABD Domain

Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model

Xu, Tianqi; Ding, Haozhong; Vorobyeva, Anzhelika; Oroujeni, Maryam et al.

Part of Cancers, 2021

• DOI for Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model
• Download full text (pdf) of Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model

Drug Occupancy Assessment at the Glucose-Dependent Insulinotropic Polypeptide Receptor by Positron Emission Tomography

Eriksson, Olof; Velikyan, Irina; Haack, Torsten; Bossart, Martin et al.

Part of Diabetes, p. 842-853, 2021

• DOI for Drug Occupancy Assessment at the Glucose-Dependent Insulinotropic Polypeptide Receptor by Positron Emission Tomography

Ga-66-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [Ga-66]Ga-NOTA-PEG(2)-RM26

Rinne, Sara S.; Abouzayed, Ayman; Gagnon, Katherine; Tolmachev, Vladimir et al.

Part of Scientific Reports, 2021

• DOI for Ga-66-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [Ga-66]Ga-NOTA-PEG(2)-RM26
• Download full text (pdf) of Ga-66-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [Ga-66]Ga-NOTA-PEG(2)-RM26

HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers

Rinne, Sara S.; Dahlsson Leitao, Charles; Abouzayed, Ayman; Vorobyeva, Anzhelika et al.

Part of Cancers, p. 4791-4791, 2021

• DOI for HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers
• Download full text (pdf) of HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model

Xu, Tianqi; Vorobyeva, Anzhelika; Schulga, Alexey; Konovalova, Elena et al.

Part of Cancers, 2021

• DOI for Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model
• Download full text (pdf) of Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model

Improved Radiolytic Stability of a ⁶⁸Ga-labelled Collagelin Analogue for the Imaging of Fibrosis

Velikyan, Irina; Rosenström, Ulrika; Rosestedt, Maria; Eriksson, Olof et al.

Part of Pharmaceuticals, 2021

• DOI for Improved Radiolytic Stability of a ⁶⁸Ga-labelled Collagelin Analogue for the Imaging of Fibrosis
• Download full text (pdf) of Improved Radiolytic Stability of a ⁶⁸Ga-labelled Collagelin Analogue for the Imaging of Fibrosis

Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1

Deyev, Sergey M.; Xu, Tianqi; Liu, Yongsheng; Schulga, Alexey et al.

Part of Cancers, 2021

• DOI for Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1
• Download full text (pdf) of Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1

PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology

Rinne, Sara S.; Orlova, Anna; Tolmachev, Vladimir

Part of International Journal of Molecular Sciences, 2021

• DOI for PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology
• Download full text (pdf) of PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology

Phase I study of ^99mTc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer

Bragina, Olga; von Witting, Emma; Garousi, Javad; Zelchan, Roman et al.

Part of Journal of Nuclear Medicine, p. 493-499, 2021

• DOI for Phase I study of ^99mTc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer

Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use

Bragina, O. D.; Chernov, V. I.; Garbukov, E. Yu; Doroshenko, A. V. et al.

Part of Bûlleten' sibirskoj mediciny, p. 23-30, 2021

• DOI for Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use
• Download full text 1 (pdf) of Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use
• Download full text 2 (pdf) of Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use

Preclinical Evaluation of ^99mTc-Labeled GRPR Antagonists maSSS/SES-PEG₂-RM26 for Imaging of Prostate Cancer

Abouzayed, Ayman; Rinne, Sara S.; Sabahnoo, Hamideh; Sörensen, Jens et al.

Part of Pharmaceutics, 2021

• DOI for Preclinical Evaluation of ^99mTc-Labeled GRPR Antagonists maSSS/SES-PEG₂-RM26 for Imaging of Prostate Cancer
• Download full text (pdf) of Preclinical Evaluation of ^99mTc-Labeled GRPR Antagonists maSSS/SES-PEG₂-RM26 for Imaging of Prostate Cancer

Preclinical Evaluation of Tc-99m-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake

Oroujeni, Maryam; Rinne, Sara S.; Vorobyeva, Anzhelika; Loftenius, Annika et al.

Part of International Journal of Molecular Sciences, 2021

• DOI for Preclinical Evaluation of Tc-99m-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake
• Download full text (pdf) of Preclinical Evaluation of Tc-99m-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake